

WHAT IS CLAIMED IS:

1. A crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol having an X-ray powder diffraction pattern comprising a peak selected from the group consisting of 8.3 ± 0.2 , 11.7 ± 0.2 , 16.7 ± 0.2 , 21.2 ± 0.2 , 24.8 ± 0.2 , 27.7 ± 0.2 , and 28.5 ± 0.2 degrees 2 theta.
2. A crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol of Claim 1 having a melting point in a range from about 213°C to about 217°C.
3. A crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol having an infrared absorption band profile comprising an absorption band at about 1644 cm^{-1} .
4. A crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol having a melting point in a range from about 213 °C to about 217°C, an infrared absorption band profile comprising an absorption band at about 1644 cm^{-1} , and an X-ray powder diffraction pattern comprising peaks at 11.7 ± 0.2 and 28.5 ± 0.2 degrees 2 theta.
5. A crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol of having an X-ray powder diffraction pattern substantially as shown in Figure 1.
6. A pharmaceutical composition comprising 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol and one or more pharmaceutically acceptable excipients, wherein a detectable amount of the 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol

is present as Form 1 crystalline 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol, wherein Form 1 has a melting point in a range from about 213 °C to about 217°C, an infrared absorption band profile comprising an absorption band at about 1644 cm⁻¹, and an X-ray powder diffraction pattern comprising peaks at 11.7 ± 0.2 and 28.5 ± 0.2 degrees 2 theta.

7. The pharmaceutical composition of Claim 6 wherein at least about 50% of the 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol is present as Form 1 crystalline 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

8. The pharmaceutical composition of Claim 6 wherein at least about 90% of the 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol is present as Form 1 crystalline 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

9. The pharmaceutical composition of Claim 6 wherein the 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol present in the composition is substantially phase pure Form 1 crystalline 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol.

10. The pharmaceutical composition of Claim 6 wherein the amount of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol present in the composition is between about 0.1 mg to about 1000 mg.

11. The pharmaceutical composition of Claim 6 wherein the amount of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol present in the composition is between about 0.1 mg to about 500 mg.

12. A method of treating or preventing a p38 kinase-mediated condition, the method comprising administering to a subject having or susceptible to such condition or disorder a therapeutically or prophylactically effective amount of the composition of Claim 6.

13. The method of Claim 12 wherein the p38 kinase-mediated condition is rheumatoid arthritis.